**Author details**

Diana Loreta Paun1,2 and Alexandra Mirica1,3\*

1 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

2 C.I. Parhon National Institute of Endocrinology, Bucharest, Romania

3 Grigore Alexandrescu Clinical Emergency Hospital for Children, Bucharest, Romania

\*Address all correspondence to: arix26@yahoo.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**21**

*Pheochromocytomas and Paragangliomas: Genotype-Phenotype Correlations*

et al. Catecholamine metabolomic

and secretory phenotypes in phaeochromocytoma. 2013;18(1):97-111.

[9] Pacak K, Wimalawansa SJ.

2011;40(2):295-311.

2018;69(3):34-6.

2019;11(4):1-15.

2015;41(4):69-76.

[11] Mirica A, Badarau IA, Stefanescu AM, Mirica R,

Paun S, Andrada D, et al. The Role of Chromogranin A in Adrenal Tumors. REVCHIM(Bucharest).

[12] Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, et al. Chromogranin a in the laboratory diagnosis of pheochromocytoma and paraganglioma. Cancers (Basel).

[13] Mirica A BI et al. Clinical use of plasma chromogranin A in

[14] Angelousi A, Peppa M, Chrisoulidou A, Alexandraki K, Berthon A, Faucz FR, et al. Malignant pheochromocytomas/paragangliomas and ectopic hormonal secretion: A case series and review of the literature.

Cancers (Basel). 2019;11(5).

[16] Main AM, Rossing M, Borgwardt L, Toft BG,

[15] Stenman A, Zedenius J, Juhlin CC. The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas—A meta-analysis and systematic review of the literature. Cancers (Basel). 2019;11(2).

neuroendocrine tumors. Curr Heal Sci J.

Pheochromocytoma and Paraganglioma. Endocr Pract. 2015;21(4):406-412.

[10] Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: Characteristics and treatment. Endocrinol Metab Clin North Am.

*DOI: http://dx.doi.org/10.5772/intechopen.95888*

Pacak K. Update of Pheochromocytoma Syndromes: Genetics, Biochemical

[2] Albattal S, Alswailem M, Moria Y, Al-Hindi H, Dasouki M, Abouelhoda M, et al. Mutational profile and genotype/ phenotype correlation of nonfamilial pheochromocytoma and paraganglioma. Oncotarget. 2019;10(57):5919-5931.

[3] Farrugia FA, charalampopoulos A. Pheochromocytoma. Endocr Regul.

Eisenhofer G, Gimenez-Roqueplo AP,

[5] Plouin PF, Amar L, Dekkers OM, Fassnach M, Gimenez-Roqueplo AP, Lenders JWM, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol.

[6] Kimura N, Takekoshi K, Naruse M. Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical Medicine. J Clin Med.

[7] Rao D, Peitzsch M, Prejbisz A, Hanus K, Fassnacht M, Beuschlein F, et al. Plasma methoxytyramine: Clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. Eur J Endocrinol.

[8] Eisenhofer G, Pacak K, Huynh T, Qin N, Bratslavsky G, Linehan WM,

Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab.

[1] Alrezk R, Suarez A, Tena I,

Evaluation, and Imaging. Front Endocrinol (Lausanne). 2018;9(November):1-13.

**References**

2019;53(3):191-212.

2014;99(6):1915-1942.

2016;174(5):G1-10.

2018;7(9):242.

2017;177(2):103-113.

[4] Lenders JWM, Duh QY,

Grebe SKG, Murad MH, et al.

*Pheochromocytomas and Paragangliomas: Genotype-Phenotype Correlations DOI: http://dx.doi.org/10.5772/intechopen.95888*
